Evaluation of Thiosulfate in End Stage Renal Disease and Kidney Transplantation

• Status: Enrolling by invitation
• Trial end date: 2023-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Kidneys retrieved from deceased donors will be randomized for conventional perfusion (University of Wisconsin: UW) with or without supplementation of thiosulfate, a major H2S metabolite, and transpl anted thereafter. Recipient's renal function will be assessed prospectively to determine if thiosulfate improves allograft function.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lawson Health Research Institute
• Treatments: Pharmaceutical Solutions; Sodium thiosulfate

Criteria

Inclusion Criteria:

• All patients >18years old who are being considered for renal transplantation at LHSC that are receiving a DCD kidney.

Exclusion Criteria:

• Age <18 years old

• Inability to give informed consent,

• Patients receiving kidneys from living donors

• Patients with known hypersensitivity to either SEACALPHYX or to any of the ingredients contained within.

• Pregnant women.

• Patients with sulfite allergies